mirtazapine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonelli, RM | 1 |
1 other study available for mirtazapine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Mirtazapine in suicidal Huntington's disease.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Huntington Disease; Mianserin; | 2003 |